Key result
Obesity is accompanied by arginase-driven microvascular endothelial dysfunction and accelerated remodeling, though the impact of arginase is reduced by aging due to higher oxidative stress.
Why the study?
Does arginase inhibition improve endothelial dysfunction in small arteries from obese patients, and is this effect modulated by aging?
Cross-Sectional
Does arginase inhibition improve endothelial dysfunction in small arteries from obese patients, and is this effect modulated by aging?
Arginase contributes to microvascular endothelial dysfunction in obesity, but its impact is blunted by aging due to increased vascular oxidative stress.
May support arginase inhibition testing in obese models; leaves open age-dependent effects in patients.
Objective— Arginase can reduce NO availability. In this study, we explored arginase as a determinant of endothelial dysfunction in small arteries from obese patients and its relationship with aging and microvascular remodeling. Approach and Results— Small arteries were dissected after subcutaneous fat biopsies and evaluated on a pressurized micromyograph. Endothelium-dependent vasodilation was assessed by acetylcholine, repeated under L-NAME ( N G -nitro-L-arginine-methyl ester), N(ω)-hydroxy-nor- l -arginine (arginase inhibitor) and gp91ds-tat (NADPH [nicotinamide adenine dinucleotide phosphate oxidase] oxidase inhibitor) in vessels from young (age <30 years) control and obese and old (>30 years) control and obese subjects. Media-lumen ratio and amount of vascular wall fibrosis were used as markers of vascular remodeling. Amount of vascular superoxide anions and NO production were determined with immunofluorescence, whereas arginase expression was quantified using Western blot and quantitative polymerase chain reaction. Obese and older age groups had lower vascular NO, as well as higher media-lumen ratio, wall fibrosis, intravascular superoxide, and blunted inhibitory effect of L-NAME on acetylcholine versus controls and younger age groups. N(ω)-hydroxy-nor- l -arginine restored the acetylcholine-induced vasodilation in young and, to a lesser extent, in old obese subjects. This effect was abolished by addition of L-NAME. Gp91ds-tat increased the vasodilatory response to N(ω)-hydroxy-nor- l -arginine in old obese. Superoxide anions and arginase I/II levels were higher in the vascular wall of obese versus controls. Conclusions— Arginase contributes to microvascular endothelial dysfunction in obesity. Its impact is reduced by aging because of higher levels of vascular oxidative stress. Obesity is accompanied by accelerated microvascular remodeling, the extent of which is related to the amount of arginase in the vascular wall.
No takes yet. Share an insight, caveat, or question.
Masi et al. (2018) conducted a cross-sectional in Obesity and endothelial dysfunction. Obesity and older age vs. Controls and younger age groups was evaluated on Endothelium-dependent vasodilation and vascular remodeling markers. Obesity is accompanied by arginase-driven microvascular endothelial dysfunction and accelerated remodeling, though the impact of arginase is reduced by aging due to higher oxidative stress.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: